» Authors » Werner Lindenmaier

Werner Lindenmaier

Explore the profile of Werner Lindenmaier including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 25
Citations 393
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Martins J, Santos J, de Almeida J, Filipe M, de Almeida M, Almeida S, et al.
Stem Cell Res Ther . 2014 Jan; 5(1):9. PMID: 24438697
Introduction: Standardization of mesenchymal stromal cells (MSCs) manufacturing is urgently needed to enable translational activities and ultimately facilitate comparison of clinical trial results. In this work we describe the adaptation...
2.
Lohmeyer J, Liu F, Kruger S, Lindenmaier W, Siemers F, Machens H
Langenbecks Arch Surg . 2011 Mar; 396(4):543-50. PMID: 21369846
Background: With the development of cell-based gene transfer techniques, genetically modified human keratinocytes (Kc) and fibroblasts (Fb) have been proven to be a better choice in wound repair. Methods: This...
3.
Garritsen H, Fan A, Lenz D, Hannig H, Zhong X, Geffers R, et al.
Transfus Med Hemother . 2010 Nov; 36(3):181-187. PMID: 21113259
Serology, defined as antibody-based diagnostics, has been regarded as the diagnostic gold standard in transfusion medicine. Nowadays however the impact of molecular diagnostics in transfusion medicine is rapidly growing. Molecular...
4.
Shahab-Osterloh S, Witte F, Hoffmann A, Winkel A, Laggies S, Neumann B, et al.
Stem Cells . 2010 Oct; 28(9):1590-601. PMID: 20882636
Ligament-to-bone and tendon-to-bone interfaces (entheses, osteotendinous junctions [OTJs]) serve to dissipate stress between soft tissue and bone. Surgical reconstruction of these interfaces is an issue of considerable importance as they...
5.
Dittmar K, Simann M, Zghoul N, Schon O, Meyring W, Hannig H, et al.
Transfus Med Hemother . 2010 Aug; 37(2):57-64. PMID: 20737047
Cellular therapies that either use modifications of a patient's own cells or allogeneic cell lines are becoming in vogue. Besides the technical issues of optimal isolation, cultivation and modification, quality...
6.
Kirschning C, Dreher S, Maass B, Fichte S, Schade J, Koster M, et al.
BMC Biotechnol . 2010 Apr; 10:31. PMID: 20388199
Background: Toll-like receptor (TLR) 2 is a component of the innate immune system and senses specific pathogen associated molecular patterns (PAMPs) of both microbial and viral origin. Cell activation via...
7.
Garritsen H, Macke L, Meyring W, Hannig H, Pagelow U, Wormann B, et al.
Transfusion . 2009 Dec; 50(4):831-42. PMID: 20003055
Background: Dendritic cells (DCs) play a central role in the initiation and regulation of immune responses. DCs for clinical applications can be generated with high yield from leukapheresis products. Using...
8.
Macke L, Garritsen H, Meyring W, Hannig H, Pagelow U, Wormann B, et al.
Transfusion . 2009 Dec; 50(4):843-55. PMID: 20003054
Background: Dendritic cells (DCs) are applied worldwide in several clinical studies of immune therapy of malignancies, autoimmune diseases, and transplantations. Most legislative bodies are demanding high standards for cultivation and...
9.
Bergmann A, Ahmad S, Cudmore M, Gruber A, Wittschen P, Lindenmaier W, et al.
J Cell Mol Med . 2009 Jun; 14(6B):1857-67. PMID: 19538465
Preeclampsia (PE) is characterized by widespread endothelial damage with hypertension, proteinuria, glomeruloendotheliosis and elevated soluble Flt-1 (sFlt-1), a natural occurring antagonist of vascular endothelial growth factor (VEGF). Cancer patients receiving...
10.
May T, Lindenmaier W, Wirth D, Mueller P
Cytotechnology . 2008 Nov; 46(2-3):69-78. PMID: 19003263
To employ physiological mechanisms to control cell growth primary cells were reversibly immortalized using the SV40 TAg. The cells showed a fibroblast-like morphology. When the expression of the TAg was...